Boston 3T joins UMass incubator

DARTMOUTH – Boston 3T Biotechnologies, an early stage pharmaceutical company developing innovative cancer-treatment technology from its headquarters in Woburn, Mass., has joined the University of Massachusetts Dartmouth’s Advanced Technology & Manufacturing Center.
The UMass center is an incubator for emerging companies like Boston 3T, providing structure and resources to help them develop into technology and manufacturing leaders in New England and beyond.
“We are excited to add Boston 3T Biotechnologies to the ATMC portfolio,” said Paul Vigeant, director of the Advanced Technology & Manufacturing Center. “We look forward to Boston 3T Biotechnologies building upon its cutting edge, innovative treatment technology and making its own mark in its development of therapies to patients.”
The scientists who founded Boston 3T have used genetically modified cytokine-induced killer cells to create a cancer-treatment technology that serves as a T cell receptor gene during cancer therapy and is integrated into the cancer patient’s own cells. The engineered gene redirects the killer cells to the tumor tissues, thereby attacking the cancerous cells and helping to reverse the suppression of immune cells.
“Our drug discovery development covers various disciplines including virology, cell biology, and immunology, protein engineering, and cancer vaccines,” said Dr. Meijia Yang, president and CEO of Boston 3T Biotechnologies. “Boston 3T Biotechnologies is dutifully committed to the development of cell-base therapies for patients and becoming a demonstrated leader in the therapeutic discovery and manufacture sciences.”
Twelve companies in the clean energy, marine technology, biotechnology and life sciences, and software industries currently occupy space at the Advanced Technology & Manufacturing Center. The center has successfully graduated 15 companies, 80 percent of which have stayed in Massachusetts to help grow the local economy, according to UMass.
The Advanced Technology & Manufacturing Center saw annual sales of over $50 million in 2013, and to date its companies have generated more than 200 jobs.

No posts to display